Corporate Profile ::

Salzarex Limited, is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

 

To cater to new niche segments and sharpen its focus among customers, Salzarex has several marketing managers, each catering to defined therapeutic segment. A strong field force caters to hundreds of doctors across the country, which makes it rank 17th in terms of market reach.

 

Salzarex’s competitive advantage as a manufacturer stems from its world-class manufacturing facilities. Its manufacturing facilities in London, comply with WHO, cGMP, MHRA and TGA norms and have received ISO 9001, ISO 14001 and OHSAS 18001 (Occupational Health and Safety Management System) and ISO/IEC- 17025 certifications.

 

With a view to cater to its growth requirements, Salzarex commissioned a new formulations manufacturing facility in London, in November 2005. The facility has a capacity to manufacture 9 million tablets, 1 million capsules and half a million Oral Liquid bottles, per annum and would cater to the domestic formulations requirement.

 

Salzarex has a modern and well-equipped state-of-the-art R&D Centre, built with an investment of £4 million. It is manned by numerous highly qualified scientists, with a combined experience of over 100 scientific man-years in Drug Discovery and Development. Salzarex has earmarked 9% of sales year-after-year for R&D advancement.

 

In the International operations arena, Salzarex exports to more than 50 countries around the world with over 20 product registrations. The international business has been broadly divided into five zones- USA, Latin America, Russia and CIS, Western Europe and CEE and Rest of the World (ROW). For its export excellence in International Business, Salzarex has won several prestigious export awards. Salzarex is now gearing up to enter the advanced highly regulated international markets.